Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sobetirome - NeuroVia

Drug Profile

Sobetirome - NeuroVia

Alternative Names: GC-1; NV 1205; QRX-431

Latest Information Update: 22 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of California at San Francisco
  • Developer NeuroVia; QuatRx Pharmaceuticals; University of California at San Francisco
  • Class Acetic acids; Antihyperlipidaemics; Benzhydryl compounds; Obesity therapies; Phenols; Small molecules
  • Mechanism of Action Thyroid hormone receptor beta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adrenoleucodystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Adrenoleucodystrophy
  • Discontinued Lipid metabolism disorders; Obesity

Most Recent Events

  • 06 Mar 2019 NeuroVia withdraws a phase I/II trial prior to enrolment due to no funding in Adrenoleucodystrophy (In children, In adolescents) in Australia, United Kingdom, Chile (PO) (NCT03196765)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Adrenoleucodystrophy in USA (PO)
  • 20 Jul 2017 Pharmacodynamics data from a preclinical trial in Adrenoleucodystrphy released by NeuroVia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top